Research Progress of Human Diploid Cells for Vaccine Production

doi:10.13523/j.cb.2106011

China Biotechnology

2021, Vol. 41

Issue (11): 74-81 DOI: 10.13523/j.cb.2106011

Research Progress of Human Diploid Cells for Vaccine Production

XIAO Yun-xi¹,ZHANG Jun-he^1,^2,^3,^**(

),YANG Wen-wen^2,³,CHENG Hong-wei¹

1 Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China
2 Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, China
3 Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang 453003, China

Download:

HTML

PDF(471KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Human diploid cells (HDCs) have attracted much attention as an important culture cell matrix for vaccine preparation. Since human diploid cells are the same as the human genome without exogenous factor, susceptible to a variety of viruses, and without potential tumorigenicity, and the preparation of human diploid cell vaccine (HDCV) has good immunogenicity and safety, they are suitable for industrial production of vaccine. Currently, the inactivated, attenuated or subunit vaccines used in the population all rely on primary cells, continuous cells and human diploid cells, of which WI-38, MRC-5, 2BS and KMB-17 cell lines are the main human diploid cells used in vaccine preparation. However, human diploid cells are limited cells, and there are some defects in cell sources and culture techniques, which further affect their application. In this paper, the research progress of human diploid cells used in vaccine production and vaccine preparation technology were reviewed, and the existing problems and improvement strategies were analyzed.

Key words： Human diploid cells Vaccine Cell line Vaccine preparation technology

Received: 08 June 2021 Published: 01 December 2021

ZTFLH:

Q819

Corresponding Authors: Jun-he ZHANG E-mail: zjh@xxmu.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yun-xi XIAO
	Jun-he ZHANG
	Wen-wen YANG
	Hong-wei CHENG

Cite this article:

XIAO Yun-xi,ZHANG Jun-he,YANG Wen-wen,CHENG Hong-wei. Research Progress of Human Diploid Cells for Vaccine Production. China Biotechnology, 2021, 41(11): 74-81.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2106011 OR https://manu60.magtech.com.cn/biotech/Y2021/V41/I11/74

Table 1 Application of main human diploid cells in vaccine development

Table 2 Effects of different cellular pathways changes in cellular genetic engineering on virus growth characteristics

Table 3 Advantages and disadvantages of viral vectors in vaccine development


[1]	Delany I, Rappuoli R, de Gregorio E. Vaccines for the 21st century. EMBO Molecular Medicine, 2014, 6(6):708-720. doi: 10.1002/emmm.v6.6

[2]	Hayflick L, Plotkin S A, Norton T W, et al. Preparation of poliovirus vaccines in a human fetal diploid cell strain. American Journal of Hygiene, 1962, 75:240-258.

[3]	Zhou X Y, Wu X H, Cai Y, et al. Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial. Human Vaccines & Immunotherapeutics, 2019, 15(4):828-833.

[4]	Olshansky S J, Hayflick L,. The role of the WI-38 cell strain in saving lives and reducing morbidity. AIMS Public Health, 2017, 4(2):127-138. doi: 10.3934/publichealth.2017.2.127 pmid: 29546209

[5]	Jacobs J P. The status of human diploid cell strain MRC-5 as an approved substrate for the production of viral vaccines. Journal of Biological Standardization, 1976, 4(2):97-99. pmid: 932048

[6]	王传林. 狂犬病疫苗研究进展. 中华实验和临床病毒学杂志, 2018, 32(3):323-327.

[6]	Wang C L. Research progress in rabies vaccine. Chinese Journal of Experimental and Clinical Virology, 2018, 32(3):323-327.

[7]	胡昭烈. 人二倍体细胞2BS株小儿麻痹活疫苗Ⅰ型安全性和免疫原性观察. 医学研究通讯, 1978, 7(11):26-30.

[7]	Hu Z L. Observation on the safety and immunogenicity of human diploid cell 2BS strain polio vaccine type I. Journal of Medical Research, 1978, 7(11):26-30.

[8]	杜桂枝, 闻仲权, 郝荣宽, 等. 人二倍体细胞2BS株制备三价脊髓灰质炎活疫苗免疫原性研究. 中国公共卫生学报, 1989, 8(2):83-85.

[8]	Du G Z, Wen Z Q, Hao R K, et al. Immunologic effect of trivalent oral poliovaccine (TOPV) prcduced in human diploid cell 2BS strain. Chinese Journal of Public Health, 1989, 8(2):83-85.

[9]	黄小琴, 杨净思, 周德久, 等. H2株甲肝病毒经KMB17细胞培养的毒力及核苷酸序列. 中国生物制品学杂志, 2000, 13(3):133-135.

[9]	Huang X Q, Yang J S, Zhou D J, et al. Virulence and nucleotide sequences of HAV (H2 strain) cultured in KMB17 cell. Chinese Journal of Biologicals, 2000, 13(3):133-135.

[10]	马应霞, 易山, 张光明, 等. 轮状病毒P[8]G1株在KMB17细胞上的适应性及其免疫原性. 中国生物制品学杂志, 2010, 23(9):942-945.

[10]	Ma Y X, Yi S, Zhang G M, et al. Adaptability of Rotavirus P[8]G1 strain in KMB17 cells and immunogenicity of adapted strain. Chinese Journal of Biologicals, 2010, 23(9):942-945.

[11]	Ma B, He L F, Zhang Y L, et al. Characteristics and viral propagation properties of a new human diploid cell line, walvax-2, and its suitability as a candidate cell substrate for vaccine production. Human Vaccines & Immunotherapeutics, 2015, 11(4):998-1009.

[12]	Wibawa T. COVID-19 vaccine research and development: ethical issues. Tropical Medicine & International Health, 2021, 26(1):14-19.

[13]	柯尊阳, 王宇, 李忠明, 等. mRNA技术及其在传染病疫苗研发中的应用. 中华微生物学和免疫学杂志, 2020, 40(9):661-667.

[13]	Ke Z Y, Wang Y, Li Z M, et al. mRNA technology for the development of vaccines against infectious diseases. Chinese Journal of Microbiology and Immunology, 2020, 40(9):661-667.

[14]	Rodrigues A F, Soares H R, Guerreiro M R, et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology. Biotechnology Journal, 2015, 10(9):1329-1344. doi: 10.1002/biot.201400387 pmid: 26212697

[15]	张燕, 石金辉, 朱梦然, 等. 新建人二倍体细胞株国内外研究概况. 国际生物制品学杂志, 2018, 41(4):179-184.

[15]	Zhang Y, Shi J H, Zhu M R, et al. Overview in research of newly established human diploid cell lines at home and abroad. International Journal of Biologicals, 2018, 41(4):179-184.

[16]	Zhang K H, Na T, Wang L, et al. Human diploid MRC-5 cells exhibit several critical properties of human umbilical cord-derived mesenchymal stem cells. Vaccine, 2014, 32(50):6820-6827. doi: 10.1016/j.vaccine.2014.07.071

[17]	Chen P, Zhang K H, Na T, et al. The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines. Scientific Reports, 2017, 7:12484. doi: 10.1038/s41598-017-11997-1

[18]	ACOG Committee Opinion No. 648: umbilical cord blood banking. Obstetrics and Gynecology, 2015, 126(6):e127-e129. doi: 10.1097/AOG.0000000000001212

[19]	Armson B A, Society of Obstetricians and Gynaecologists of Canada M M C. Umbilical cord blood banking: implications for perinatal care providers. Journal of Obstetrics and Gynaecology Canada, 2005, 27(3):263-290. doi: 10.1016/S1701-2163(16)30520-5

[20]	Grieco D, Lacetera N, Macis M, et al. Motivating cord blood donation with information and behavioral nudges. Scientific Reports, 2018, 8:252. doi: 10.1038/s41598-017-18679-y

[21]	Wang T, Zhang J, Liao J Q, et al. Donor genetic backgrounds contribute to the functional heterogeneity of stem cells and clinical outcomes. Stem Cells Translational Medicine, 2020, 9(12):1495-1499. doi: 10.1002/sct3.v9.12

[22]	Costa L A, Eiro N, Fraile M, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cellular and Molecular Life Sciences, 2021, 78(2):447-467. doi: 10.1007/s00018-020-03600-0

[23]	Yeo J H M, Ho S C L, Mariati M, et al. Optimized selection marker and CHO host cell combinations for generating high monoclonal antibody producing cell lines. Biotechnology Journal, 2017, 12(12):1700175. doi: 10.1002/biot.v12.12

[24]	Fan L C, Kadura I, Krebs L E, et al. Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells. Biotechnology and Bioengineering, 2012, 109(4):1007-1015. doi: 10.1002/bit.24365

[25]	Mensah E O, Guo X Y, Gao X D, et al. Establishment of DHFR-deficient HEK293 cells for high yield of therapeutic glycoproteins. Journal of Bioscience and Bioengineering, 2019, 128(4):487-494. doi: 10.1016/j.jbiosc.2019.04.005

[26]	Moulia-Pelat J P, Spiegel A, Martin P M V, et al. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine, 1994, 12(6):499-502. pmid: 8036822

[27]	Zhang W, Han L L, Lin C Y, et al. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine. Vaccine, 2011, 29(37):6276-6282. doi: 10.1016/j.vaccine.2011.06.045 pmid: 21722684

[28]	Rodrigues A F, Carrondo M J T, Alves P M, et al. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells. Trends in Biotechnology, 2014, 32(12):602-607. doi: 10.1016/j.tibtech.2014.09.010 pmid: 25450042

[29]	鲁国涛, 王辉, 曾为俊, 等. 利用CRISPR/Cpf1技术构建HEK293细胞DDX21基因稳定敲除株及功能鉴定. 中国兽医学报, 2020, 40(2):257-263.

[29]	Lu G T, Wang H, Zeng W J, et al. Construction of DDX21 knockout gene stable strain using CRISPR/Cpf1 gene editing technology and identification of functions. Chinese Journal of Veterinary Science, 2020, 40(2):257-263.

[30]	Zhang W F, Xiao D, Shan L L, et al. Generation of apoptosis-resistant HEK293 cells with CRISPR/Cas mediated quadruple gene knockout for improved protein and virus production. Biotechnology and Bioengineering, 2017, 114(11):2539-2549. doi: 10.1002/bit.v114.11

[31]	Gallo-Ramírez L E, Nikolay A, Genzel Y, et al. Bioreactor concepts for cell culture-based viral vaccine production. Expert Review of Vaccines, 2015, 14(9):1181-1195. doi: 10.1586/14760584.2015.1067144 pmid: 26178380

[32]	唐取来, 顾力行, 周勇, 等. 机械搅拌式生物反应器悬浮培养293T细胞生产慢病毒的工艺. 河南农业大学学报, 2021, 55(2):314-320.

[32]	Tang Q L, Gu L X, Zhou Y, et al. Producing Lentivirus by suspension culture of 293T cells in a stirred bioreactor. Journal of Henan Agricultural University, 2021, 55(2):314-320.

[33]	Venereo-Sanchez A, Gilbert R, Simoneau M, et al. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: an effective influenza vaccine candidate. Vaccine, 2016, 34(29):3371-3380. doi: 10.1016/j.vaccine.2016.04.089 pmid: 27155499

[34]	Rourou S, Ben Zakkour M, Kallel H. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media. Vaccine, 2019, 37(47):6987-6995. doi: S0264-410X(19)30749-2 pmid: 31201054

[35]	Petiot E, Cuperlovic-Culf M, Shen C F, et al. Influence of HEK293 metabolism on the production of viral vectors and vaccine. Vaccine, 2015, 33(44):5974-5981. doi: 10.1016/j.vaccine.2015.05.097 pmid: 26073013

[36]	Shirvani E, Samal S K. Newcastle disease virus as a vaccine vector for SARS-CoV-2. Pathogens, 2020, 9(8):619. doi: 10.3390/pathogens9080619

[37]	Zaiss A K, Machado H B, Herschman H R. The influence of innate and pre-existing immunity on adenovirus therapy. Journal of Cellular Biochemistry, 2009, 108(4):778-790. doi: 10.1002/jcb.22328 pmid: 19711370

[38]	王传林, 李明, 吕新军. 人用疫苗的分类及生产工艺. 中华预防医学杂志, 2020, 54(9):1017-1025. doi: 10.3760/cma.j.cn112150-20200520-00756 pmid: 32907295

[38]	Wang C L, Li M, Lu X J. Classification and production process of human vaccine. Chinese Journal of Preventive Medicine, 2020, 54(9):1017-1025. doi: 10.3760/cma.j.cn112150-20200520-00756 pmid: 32907295

[39]	李莉莉, 周玉柏, 曾毅. 改良型痘苗病毒安卡拉株(MVA)作为递送载体在抗感染治疗中的应用. 中华微生物学和免疫学杂志, 2015, 35(7):550-555.

[39]	Li L L, Zhou Y B, Zeng Y. Modified vaccinia virus Ankara (MVA) is used as a delivery vector in anti-infective treatment. Chinese Journal of Microbiology and Immunology, 2015, 35(7):550-555.

[40]	Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. The Journal of General Virology, 1991, 72(Pt 5):1031-1038. doi: 10.1099/0022-1317-72-5-1031

[41]	Garber D A, O’Mara L A, Zhao J, et al. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One, 2009, 4(5):e5445. doi: 10.1371/journal.pone.0005445

[42]	Alharbi N K. Poxviral promoters for improving the immunogenicity of MVA delivered vaccines. Human Vaccines & Immunotherapeutics, 2019, 15(1):203-209.

[43]	Sutter G. A vital gene for modified vaccinia virus Ankara replication in human cells. PNAS, 2020, 117(12):6289-6291. doi: 10.1073/pnas.2001335117 pmid: 32179684

[44]	Liu R K, Mendez-Rios J D, Peng C, et al. SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells. PLoS Pathogens, 2019, 15(5):e1007710. doi: 10.1371/journal.ppat.1007710

[45]	Cho S H, Kwon H J, Kim T E, et al. Characterization of a recombinant Newcastle disease virus vaccine strain. Clinical and Vaccine Immunology, 2008, 15(10):1572-1579. doi: 10.1128/CVI.00156-08

[46]	Sun W N, Leist S R, S, et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62:103132. doi: 10.1016/j.ebiom.2020.103132

[47]	Silveira M M, Moreira G M S G, Mendonça M. DNA vaccines against COVID-19: Perspectives and challenges. Life Sciences, 2021, 267:118919. doi: 10.1016/j.lfs.2020.118919

[1]	ZHU Xiao-jing,WANG Rui,ZHANG Xin-xin,JIN Jia-xin,LU Wen-long,DING Da-shun,HUO Cui-mei,LI Qing-mei,SUN Ai-jun,ZHUANG Guo-qing. Construction of MDV Recombinant Vaccine Strain Integrated F Gene Using Bacterial Artificial Chromosome Technique[J]. China Biotechnology, 2021, 41(10): 33-41.

[2]	CHENG Xu,YANG Yu-qing,WU Sai-nan,HOU Qin-long,LI Yong-mei,HAN Hui-ming. *Construction of DNA Vaccines of Staphylococcus aureus SarA, IcaA* and Their Fusion Genes and Preliminary Study in Mouse Immune Response**[J]. China Biotechnology, 2020, 40(7): 41-50.

[3]	LIU Zhen-zhen,TIAN Da-yong. Development of Sucrose Density Gradient Centrifugation Purification Process for Rabies Vaccine[J]. China Biotechnology, 2020, 40(4): 25-33.

[4]	QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.

[5]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[6]	JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.

[7]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[8]	FENG Xue-jiao,HOU Hai-long,YU Qiong,WANG Jun-shu. Market Analysis and Countermeasures of Cervical Cancer Vaccine in China[J]. China Biotechnology, 2020, 40(11): 96-101.

[9]	Yan GAO,Jing-jing DU,Bin WANG,Qi LIU,Zhi-qiang SHEN. Study on β-Propiolactone in Inactivation Process of Rabies Vaccine by Gas Chromatography[J]. China Biotechnology, 2019, 39(6): 25-31.

[10]	Lin YANG,Zhe-yan FU,Zheng-bing LV,Jian-hong SHU. Classification and Mechanism of Immune Adjuvant[J]. China Biotechnology, 2019, 39(5): 114-119.

[11]	Yi-fan JIANG,Jing DONG,Jing-shuang WEI. Monoclone Selection and Monoclonal Verification of Engineering Cell Lines[J]. China Biotechnology, 2019, 39(4): 101-105.

[12]	Jia-yue XU,Zi-qian LI,Ge ZHANG. Advanced in Research Dengue Virus 3'UTRΔ30 Series Vaccines[J]. China Biotechnology, 2019, 39(3): 97-104.

[13]	Fu-lan GAO,Jia-long QI,Cong-yan SHU,Hang-hang XIE,Wei-wei HUANG,Cun-bao LIU,Xu YANG,Wen-jia SUN,Hong-mei BAI,Yan-bing MA. Efficient Secretory Expression of Optimized Mouse Interleukin-33 Gene in Mammalian Cells[J]. China Biotechnology, 2019, 39(3): 46-55.

[14]	Xi-wen JIANG,Zi-wei DONG,Yue LIU,Xiao-ya ZHU. Reserch Progress on Biomarkers and Precision Medicine[J]. China Biotechnology, 2019, 39(2): 74-81.

[15]	SUN Si,QIU Yu-lan,YAN Ju-rong,YANG Jing,WU Guang-ying,WANG Lin,XU Wen-chun. *Recombinant Plasmid pcDNA3-dnaJ* Prime/DnaJ Protein Boost Immunization Induce Th1/Th17 Immune Responses and Protect Mice Against Pneumococcal Infection**[J]. China Biotechnology, 2019, 39(12): 9-17.

Viewed

Full text

Abstract

Cited

Shared

Discussed